drugset / Trial / NCT00113308

COX-2 Inhibitor Study In Patients With Rheumatoid Arthritis

NCT00113308 ↗

Phase 3 Completed 2208 enrolled GlaxoSmithKline
RandomizedSingle-groupDouble-blindTreatment

Summary

This study is being conducted to find out if an investigational drug called GW406381 can help people with rheumatoid arthritis.

Timeline

Start
2005-06
Primary completion
2006-09
Completion
2006-09

Drugs

EvaluationDrugModalityDoseRoute
Subject GW406381 Small molecule 5 mg Oral
Subject GW406381 Small molecule 10 mg Oral
Subject GW406381 Small molecule 25 mg Oral
Subject GW406381 Small molecule 50 mg Oral

Indications